Filing summary
Important identification note: The supplied filing is Caladrius Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 22, 2022. It does not match the request metadata identifying Lisata Therapeutics or “2020 Q4.” The summary below reflects the filing text.
Business context and reporting period
Caladrius was a clinical-stage biopharmaceutical company developing autologous CD34+ cell therapies. Its principal programs were XOWNA (CLBS16) for coronary microvascular dysfunction (CMD), HONEDRA (CLBS12) for critical limb ischemia and Buerger’s disease, and CLBS201 for diabetic kidney disease. The filing covers fiscal 2021 and compares results with fiscal 2020.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue from product sales | None; the company reported no product-sales revenue | None |
| Research and development expense | $17.7 million | $9.3 million |
| General and administrative expense | $11.4 million | $9.9 million |
| Total operating expenses / operating loss | $29.1 million | $19.1 million |
| Net loss | $27.5 million | $8.1 million |
| Basic and diluted loss per share | $0.50 | $0.53 |
| Net cash used in operating activities | $22.2 million | $8.8 million |
- At year-end 2021, cash and cash equivalents were $24.6 million and marketable securities were $70.3 million, totaling approximately $95.0 million. Working capital was $91.7 million and stockholders’ equity was $92.3 million.
- Operating cash use increased as development activity expanded, particularly enrollment costs for XOWNA’s Phase 2b study. Investing cash outflow was $54.9 million, primarily reflecting net purchases of marketable securities; financing provided $85.3 million, principally through equity and warrant-related transactions.
- Total liabilities were $5.0 million, including $4.5 million of current liabilities and $0.7 million of operating lease liabilities. The filing reports no borrowings or cash interest payments.
- The $1.5 million income-tax benefit in 2021 primarily reflected proceeds from selling New Jersey net operating losses. The comparable 2020 tax benefit was $10.9 million, a major factor in the year-over-year increase in reported net loss.
- Margins are not meaningful given the absence of product-sales revenue and the company’s development-stage operations.
Material changes versus 2020
- Net loss increased to $27.5 million from $8.1 million; operating expenses rose 52% to $29.1 million. R&D expense increased 91%, mainly due to XOWNA Phase 2b activity and continued program costs.
- Operating cash use rose to $22.2 million from $8.8 million.
- Cash, cash equivalents and marketable securities increased to $95.0 million from $34.6 million, following substantial 2021 equity financings.
- Common shares outstanding increased from 19.4 million at year-end 2020 to 59.8 million at year-end 2021. The company also reported 21.4 million outstanding warrants at year-end 2021.
Outlook, risks and unusual items
- Management said existing cash was expected to fund operating expenses for at least 12 months after issuance of the financial statements, while also stating that substantial additional financing would be needed to continue operations and development. No formal revenue or earnings guidance was provided.
- HONEDRA enrollment in Japan was suspended amid COVID-19-related delays and costs; the company was seeking a Japanese development partner and consulting with regulators about possible use of accrued data. It decided not to pursue U.S. Buerger’s disease development at that time.
- XOWNA’s U.S. Phase 2b FREEDOM trial continued, but enrollment was delayed by COVID-19; protocol amendments agreed with the FDA were intended to improve enrollment. CLBS201 advanced to a small, open-label Phase 1 proof-of-concept study planned for six subjects.
- Key risks include continued operating losses and financing needs, clinical and regulatory uncertainty, enrollment delays, manufacturing dependence on third parties, potential shareholder dilution, and uncertain commercialization and reimbursement prospects.
- On February 18, 2022, Nasdaq notified the company that it did not meet the $1.00 minimum bid-price requirement. The filing states the compliance period ran through August 17, 2022; the deficiency also restricted sales under the company’s $50 million ATM facility until compliance was regained.
- The auditor issued an unqualified opinion and reported no critical audit matters. Management said disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to express an opinion on internal-control effectiveness. The company said ordinary-course legal proceedings were not expected to have a material effect.
Important facts for investors to verify
- Confirm the intended issuer and period: the source is Caladrius Biosciences’ FY2021 10-K, not a Lisata Therapeutics 2020 Q4 filing.
- Check subsequent cash burn, financing activity, and the accuracy of management’s stated minimum 12-month cash runway.
- Verify current status and enrollment progress for XOWNA and CLBS201, and whether HONEDRA obtained a partner or a regulatory path in Japan.
- Assess dilution from the 2021 offerings and outstanding warrants, options, restricted stock units, and any later equity issuance.
- Check the outcome of the Nasdaq bid-price deficiency and whether the ATM facility became available for use.